Prior view was EUR 13B-EUR 17B. The updated guidance reflects the shipment of the Omicron-adapted bivalent vaccine boosters, which started early in September and is expected to continue throughout the fourth quarter of 2022 as well as higher prices and a positive foreign currency effect. This revenue estimate reflects expected revenues related to BioNTech’s (BNTX) share of gross profit from COVID-19 vaccine sales in the collaboration partners’ territories, from direct COVID-19 vaccine sales to customers in BioNTech’s territory and expected revenues generated from products manufactured by BioNTech and sold to collaboration partners. BioNTech’s COVID-19 vaccine gross profit share from Pfizer (PFE) is impacted by inventory write-offs. Pfizer inventory write-offs for COVID-19 products reduce BioNTech’s gross profit share and therefore, reduce BioNTech’s vaccine revenues.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BNTX:
- BioNTech’s Q3 Results Disappoint
- BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update
- Pfizer, BioNTech update data on omicron BA.4/BA.5-adapted bivalent booster
- Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
- VAXED-out: The Demise of Vaccine Makers Continues